Legal Cannabis: A Year in Review

The first year for cannabis legalization has been a bumpy ride, especially for stocks like Canopy Growth Corp. (TSX:WEED)(NYSE:CGC).

| More on:
edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

It’s been exactly one year and a day since the legalization of recreational cannabis in Canada. I’m happy to report that the first year has been a stunning success.

Canada’s provinces have been forward-thinking in constructing a progressive cannabis policy that favours consumers. Overall, Canada has delivered a stellar experience that has set an example worldwide.

Just kidding! Legalization was met with tremendous excitement early on, but the industry was struck by supply issues in the opening weeks. Provinces like Ontario and Quebec have been mired in debate over cannabis’ retail footprint, and even now accessibility is a problem. The wishy-washy rollout has allowed the black market to rebuild its footprint in the sector.

Let’s review the bad and the good for the sector over the past several months, and then I will give a final grade for the one-year anniversary.

Big producers are pushing for profitability

Shares for the largest producers have encountered volatility since last spring. Canopy Growth (TSX:WEED)(NYSE:CGC) stock has dropped 42% over the past three months as of early afternoon trading on October 18.

In the first quarter, Canopy Growth reported a hefty $1.28 billion loss compared to a $91 million loss in Q1 fiscal 2019. The company said that most of the loss was due to a $1.18 billion non-cash loss on the extinguishing of warrants held by its partner, Constellation Brands.

Canopy Growth was forced to push back its forecast for profitability after the disappointing quarter. The company says that it will now require another three to five years before it’s able to turn a profit.

On the bright side, Canopy Growth is flush with cash and investing aggressively on a global scale. Contrast its early setbacks with Aurora Cannabis, which has also been forced to push back its profitability forecast while wrestling with cash issues.

The dawn of “Cannabis 2.0”

The next round of cannabis legalization got underway yesterday. Edibles are now legal for recreational consumption, although products will not officially launch until December. These products will range from chocolates, to gummy candies, to cannabis-infused beer. The new law limits edibles to containing 10 milligrams of THC.

Industry experts expect that this new wave of legalization will bring in fresh customers. Consumers who are uncomfortable with smoking or vaping now have alternative methods. The edibles market in Colorado has grown to over one-third of total sales.

A study by Deloitte estimated that the market for cannabis edibles could be worth roughly $2.7 billion a year in Canada. The report projects that more than $1.6 billion will be spent annually on edibles and nearly $530 million on cannabis-infused drinks.

This explosive potential is one of the reasons I’d recommended investors try to get in early on stocks that are positioned to benefit from this new wave of legalization.

The grade so far: C

The rollout for recreational cannabis has been predictably chaotic, and there are major areas for improvement in the second year. Consumer accessibility is something provinces will need to work on in order to combat the black market.

This means more retail locations in provinces like Ontario and Quebec. Supply issues should be in the rear-view mirror in 2020 as producers draw closer to their production targets.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »